Clinical trial register · Japan

Clinical Trials in Kashiwa, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC

2493

Studies in scope

all four open statuses

1263

Recruiting now

open to new participants

349

Lead sponsors

across recruiting studies

Top sites

Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348

Trials with a site in Kashiwa

Status

Study

Lead sponsor

Phase

Enrol

Sites in Japan

Start

Not yet open

HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding

NCT07753005Hemorrhage, Gastrointestinal Hemorrhage, Hemoptysis, Postpartum Hemorrhage

Aesculap AG

Observational

176

Nagoya, Toyoake, Kashiwa, Gifu, Sapporo, Nishinomiya, Kawasaki, Kashihara

2026-09-30

Recruiting

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer

DrugsPatritumab deruxtecan·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1/2

220

Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka

2026-09-17

Recruiting

A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

NCT07734116Pediatric Malignant Solid Tumor and Epithelioid Sarcoma

DrugONO-4538HSC

Ono Pharmaceutical Co., Ltd.

Phase 1/2

Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto

2026-09-15

Recruiting

First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

NCT07681882Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor

Daiichi Sankyo

Phase 1

Kashiwa, Osaka, Tokyo

2026-08-06

Recruiting

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

NCT07617337ALK Positive Non-small Cell Lung Cancer

DrugLorlatinib

Chugai Pharmaceutical

Phase 1

102

Nagoya, Kashiwa, Sakai, Nagaizumi-cho, Chuo-ku, Koto-Ku

2026-07-24

Recruiting

Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

NCT07618377Gastrointestinal Stromal Tumors

DrugRipretinib

Ono Pharmaceutical Co., Ltd.

Phase 1

Kashiwa, Tokyo

2026-07-07

Recruiting

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

NCT07787208Solid Tumors

Ono Pharmaceutical Co., Ltd.

Phase 1

Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun

2026-06-19

Recruiting

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

NCT07660055Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer

Novartis Pharmaceuticals

Phase 1

156

Kashiwa

2026-06-16

Active, closed

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

DrugsTNO155·Opnurasib·Trametinib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Kashiwa, Koto Ku

2026-06-08

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856Colitis, Ulcerative

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

644

Bunkyō City, Hamamatsu, Higashi-Ibaraki, Kagoshima, Kashiwa, Kumamoto, Minatoku, Mitaka

2026-05-23

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843Crohn Disease

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

460

Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku

2026-05-22

Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

NCT07539311Gastrointestinal Cancers

DrugRina-S

Genmab

Phase 2

160

Kashiwa, Yokohama, Suita, Kōtoku

2026-05-11

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe

2026-05-04

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC

DrugsRina-S·Bevacizumab

Genmab

Phase 3

544

Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume

2026-04-03

Recruiting

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

DrugZotemtegrast

Eli Lilly and Company

Phase 2

1,431

Asahikawa, Bunkyō City, Fujiidera, Fukuoka, Hirosaki, Kagoshima, Kashiwa, Mitaka

2026-03-26

Recruiting

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855Solid Tumours

DrugSaruparib

AstraZeneca

Phase 1/2

180

Chūōku, Kashiwa

2026-03-17

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076Hepatocellular Carcinoma (HCC)

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

198

Osakasayama-shi, Kashiwa

2026-03-16

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita

2026-03-13

Recruiting

A Randomized Controlled Trial of a Multi-domain Smartphone Intervention Incorporating Generative AI for Healthy Older Adults

NCT07524478Healthy Longevity

Tatsuhiro Hisatsune

Not applicable

300

Kashiwa

2026-03-10

Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsCetuximab·Nab-paclitaxel·Gemcitabine

Revolution Medicines, Inc.

Phase 3

900

Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama

2026-03-09

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku

2026-02-23

Recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

DrugsLevofolinate·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Global Development, Inc.

Phase 3

614

Kashiwa, Matsuyama, Fukuoka, Kashihara-shi, Sakai, Suita, Bunkyo-ku, Koto

2026-02-17

Recruiting

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

NCT07432295Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer

DrugsGivastomig·5Fluorouracil·Leucovorin·Adrucil

I-Mab Biopharma US Limited

Phase 2

180

Kashiwa, Tokyo

2026-02-11

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi

2026-02-03

Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer

DrugsSigvotatug vedotin·PF-08634404

Pfizer

Phase 1/2

162

Kashiwa, Sendai, Hirakata, Nagaizumi-cho, Bunkyo-ku

2026-01-30

Active, closed

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT07336446Prostate Cancer

DrugSaruparib

AstraZeneca

Phase 1/2

Kashiwa

2026-01-27

Recruiting

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07185009Ulcerative Colitis

DrugDuvakitug

Sanofi

Phase 3

751

Bunkyō City, Chikushino-shi, Hachiōji, Kagoshima, Kamakura, Kashiwa, Kobe, Kōriyama

2026-01-16

Recruiting

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

DrugPosaconazole

AstraZeneca

Phase 1/2

Bunkyō City, Kashiwa, Okayama

2026-01-09

Recruiting

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

NCT07174427Synovial Sarcomas

DrugsTBI-1301·Fludarabine·Cyclophosphamide

Takara Bio Inc.

Phase 3

Osaka, Fukuoka, Kashiwa

2026-01-05

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Nagoya, Kashiwa, Otashi, Sapporo, Himeji, Kobe, Shiwa-gun Yahaba-cho, Kawasaki

2026-01-02

Recruiting

A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

NCT07287748DTC - Differentiated Thyroid Cancer

Alpha Fusion Inc.

Phase 1

Kashiwa

2026-01-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Nagoya, Toyoake, Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Yokohama

2025-12-31

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Akashi-shi, Chūōku, Hidaka-shi, Kashiwa, Kobe, Kōtoku, Kurume-shi, Nagoya

2025-12-29

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

480

Nagoya, Toyoake, Kashiwa, Kurume-Shi, Sapporo, Akashi-shi, Natori-shi, Niigata

2025-12-17

Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

DrugsVepugratinib·Pembrolizumab

Eli Lilly and Company

Phase 3

450

Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe

2025-12-12

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Nagoya, Chiba, Kashiwa, Yokohama, Hidaka, Kitaadachi-gun, Nagaizumi-cho, Koto-ku

2025-12-11

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

Kashiwa, Yokohama, Chūō, Koto, Osaka

2025-12-04

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi

2025-12-04

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Hirakata, Kashiwa, Nagoya, Sapporo, Shinjuku, Sunto Gun, Tokyo

2025-12-03

Recruiting

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

NCT07227012Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma

DrugsPF-08634404·Yervoy·Ipilimumab

Pfizer

Phase 1/2

138

Nagoya, Kashiwa, Sakai, Chuo-ku, Fukuoka

2025-12-01

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi

2025-11-24

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

Bunkyō City, Chūōku, Kashiwa

2025-11-12

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Fukuoka, Kamakura, Kashiwa, Osaka, Sakura, Sapporo

2025-11-10

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Nagoya, Kashiwa, Tōon, Kurume, Sapporo, Nishinomiya, Yokohama, Sendai

2025-11-05

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama

2025-10-31

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Nagoya, Kashiwa, Sapporo, Yokohama, Chuo-ku, Koto, Osaka

2025-10-23

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya

2025-10-22

Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor

Zymeworks BC Inc.

Phase 1

140

Kashiwa, Kyoto, Osaka, Tokyo

2025-10-21

Recruiting

A Study of DS3610a in Participants With Advanced Solid Tumor

NCT07159126Solid Tumors, Metastatic Solid Tumors

Daiichi Sankyo

Phase 1

Chūōku, Kashiwa

2025-10-09

Recruiting

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

NCT07107490Extensive Stage Small Cell Lung Cancer

DrugObinutuzumab

Chugai Pharmaceutical

Phase 1

122

Kashiwa, Tōon, Sakai, Niigata

2025-10-08

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Nagoya, Chiba, Kashiwa, Kita-gun, Kawasaki, Yokohama, Suita, Nagaizumi-cho

2025-10-03

Recruiting

A Study of DS5361b in Participants With Advanced Solid Tumors

NCT07182591Advanced Solid Tumor

DrugsKeytruda·Pembrolizumab

Daiichi Sankyo

Phase 1

192

Kashiwa, Kōtoku

2025-10-02

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Chūōku, Kashiwa, Kōtoku

2025-10-01

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Chūōku, Hirakata-shi, Kashiwa

2025-09-30

Not yet open

LTFU for All Cell and Gene Therapy Studies

NCT06194461Hepatocellular Carcinoma, Prostate Cancer

DrugsAZD0754·AZD5851

AstraZeneca

Observational

Kashiwa, Kyoto, Osakasayama-shi

2025-09-17

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Kashiwa, Sendai, Hirakata

2025-09-09

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama

2025-09-02

Recruiting

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone

Astellas Pharma Global Development, Inc.

Phase 2

218

Kashiwa, Sunto-gun, Bunkyo-ku, Koto, Fukuoka, Osaka

2025-08-19

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

Chiba, Kashiwa, Matsuyama, Otashi, Isehara, Yokohama, Suita, Bunkyo-ku

2025-08-05

Recruiting

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer

DrugsPalbociclib·Fulvestrant

Bristol-Myers Squibb

Phase 1

234

Kashiwa, Hirakata, Chuo-ku, Koto-ku

2025-08-01

Recruiting

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Sacituzumab tirumotecan·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

298

Nagoya, Kashiwa, Chūō

2025-07-30

Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

120

Chūōku, Kashiwa

2025-07-29

Recruiting

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

NCT07018570Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsLevofolinate·Fluorouracil·Adrucil·Docetaxel

National Cancer Center Hospital East

Phase 2

Kashiwa

2025-07-24

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631Metastatic Colorectal Cancer

DrugsBNT314·Pumitamig·Bevacizumab

BioNTech SE

Phase 1/2

482

Chūōku, Kashiwa

2025-07-18

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Chūōku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osaka

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsLeucovorin/levofolinate calcium·Bevacizumab biosimilar·Calderasib·Mvasi

Merck Sharp & Dohme LLC

Phase 3

477

Nagoya, Kashiwa, Sapporo, Kita-gun, Yokohama, Sendai, Sakai, Hidaka

2025-07-16

Active, closed

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722Ulcerative Colitis

DrugBrivekimig

Sanofi

Phase 2

105

Kashiwa, Ōita, Hamamatsu, Hirosaki, Morioka, Nishinomiya

2025-07-07

Recruiting

Study of AUBE00 in Patients With Solid Tumors

NCT07030959Solid Tumors

DrugCetuximab

Chugai Pharmaceutical

Phase 1

130

Kashiwa, Chuo-ku

2025-06-05

Recruiting

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Kashiwa, Ōita, Hamamatsu, Bunkyō City, Hirosaki, Morioka, Nishinomiya

2025-06-03

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Kashiwa, Sakura, Chikushino-shi, Maebashi, Shiwa-gun, Yokohama, Tsu, Sendai

2025-05-27

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Chiba, Kashiwa, Matsuyama, Fukuoka, Maebashi, Sapporo, Akashi-shi, Kobe

2025-05-22

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe

2025-05-06

Active, closed

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

AstraZeneca

Phase 1/2

Chūōku, Kashiwa, Kōtoku

2025-04-29

Active, closed

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

NCT06816108Solid Tumor, NSCLC

Ono Pharmaceutical Co., Ltd.

Phase 1

Nagoya, Kashiwa, Kurume, Nishinomiya, Sagamihara, Yokohama, Nankoku, Kyoto

2025-04-21

Recruiting

Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

NCT07100704Recurrent/ Metastatic Olfactory Neuroblastoma

DrugNivolumab

National Cancer Center Hospital East

Phase 2

Kashiwa, Shimotsuke

2025-04-15

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Shiwa-gun

2025-04-09

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Chūōku, Hiroshima, Kashiwa, Kita-gun, Kobe, Kōtoku, Matsuyama, Nagoya

2025-03-27

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Akashi-shi, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa, Kashiwa-shi, Kobe, Kōtoku

2025-03-27

Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022Hepatocellular Carcinoma

AstraZeneca

Phase 1/2

304

Kashiwa, Yokohama

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kōtō City

2025-03-27

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

Kashiwa, Koto, Osaka

2025-03-25

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128MTAP-deleted Solid Tumors

Bayer

Phase 1/2

450

Nagoya, Kashiwa, Sakai, Sunto, Chuo-ku, Koto-ku

2025-03-21

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Nagoya, Kashiwa, Matsuyama, Sapporo, Kahoku-gun, Isehara, Kawasaki, Sagamihara

2025-03-16

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Nagoya, Kashiwa, Nishinomiya, Kanazawa, Shibuya-ku, Fukuoka, Kumamoto, Okayama

2025-03-12

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

Kashiwa, Tokyo

2025-02-28

Recruiting

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670Prostate Cancer

DrugAAA817

Novartis Pharmaceuticals

Phase 2/3

443

Kashiwa, Sapporo, Kobe, Yokohama, Chiba, Fukuoka, Fukushima, Ishikawa

2025-02-27

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Nagoya, Kashiwa, Hirakata, Koto

2025-02-27

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

Nagoya, Kashiwa, Sapporo, Sakai, Chuo-ku, Koto-ku

2025-02-13

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Nagoya, Kashiwa, Matsuyama, Kobe, Kanazawa, Isehara, Sendai, Sakai

2025-01-27

Recruiting

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076NSCLC (Advanced Non-small Cell Lung Cancer)

BlossomHill Therapeutics

Phase 1/2

675

Kashiwa, Osakasayama-shi, Tsukiji

2025-01-09

Active, closed

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors

DrugR-DXd

Daiichi Sankyo

Phase 2

335

Akashi, Chūōku, Fukuoka, Hidaka, Kashiwa, Kōtoku, Nagoya, Osaka

2025-01-06

Active, closed

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin

Institut de Recherches Internationales Servier

Phase 1/2

Kashiwa, Chūōku, Kyoto, Yokohama

2024-12-16

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Sakai, Shizuoka, Suita

2024-12-12

Recruiting

Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients

NCT06673628Angiosarcoma of Skin, Angiosarcoma Metastatic

DrugsLenvatinib·Pembrolizumab

National Cancer Center, Japan

Phase 2

Kashiwa, Kyoto, Miyazaki, Nagoya, Tokyo

2024-12-01

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama

2024-11-27

Active, closed

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT06644768Non-small Cell Lung Cancer, Lung Cancer

DrugsValemetostat·Valemetostat Tosylate·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 1/2

137

Fukuoka, Kashiwa, Kōtoku, Nagoya, Sagamihara-shi

2024-10-30

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka

2024-10-22

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Kashiwa, Kitakyushu, Kawasaki, Yokohama, Hirakata, Sakai, Sunto-gun, Shimotsuga-gun

2024-10-21

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

600

Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka

2024-10-21

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Chiba, Chūōku, Kashiwa, Nagoya, Osaka, Shizuoka, Suita, Tokyo

2024-10-18

Active, closed

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844Non-small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Vinorelbine·Etoposide

AstraZeneca

Phase 3

Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa

2024-10-15

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Nakamura-ku,Nagoya, Kashiwa, Kitakyushu, Kurume, Fukuyama-shi, Sapporo, Sagamihara, Yokohama

2024-10-07

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Nagoya, Kashiwa, Fukuoka, Hiragi, Natori-shi, Sendai, Ōsaka-sayama, Chuo Ku

2024-09-25

Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin

Eli Lilly and Company

Phase 1

340

Chūōku, Kashiwa, Kōtō City, Nagaizumi-cho,Sunto-gun, Nagoya

2024-09-19

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Chūōku, Kashiwa

2024-09-18

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

Nagoya, Kashiwa, Sapporo, Himeji, Kobe, Sagamihara, Sendai, Hirakata

2024-08-28

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Kashiwa, Yokohama

2024-08-22

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi

2024-08-12

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto

2024-08-01

Recruiting

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

NCT06476184Ovarian Cancer

DrugsPaclitaxel·Carboplatin

ARCAGY/ GINECO GROUP

Phase 3

250

Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume

2024-07-30

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ohta, Sapporo, Tsukuba

2024-07-24

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Himeji-shi, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Nagaizumi-cho, Niigata, Okayama

2024-07-22

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Nagoya, Chiba, Kashiwa, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kagoshima

2024-07-19

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Chūōku, Fukuoka, Kashiwa, Miki, Nagoya, Natori, Ōsaka-sayama, Sendai

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Nagoya, Kashiwa, Ōta, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama

2024-06-24

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

Kashiwa, Yokohama

2024-06-20

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Nagoya, Kashiwa, Eiheiji-cho,Yoshida-gun, Ōgaki, Sapporo, Amagasaki, Himeji, Kanazawa

2024-06-19

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Nagoya, Toyoake, Hirosaki, Kashiwa, Tōon, Ōta, Kobe, Takarazuka

2024-06-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Nagakute, Nagoya, Abiko, Kashiwa, Sakura, Kurume, Maebashi, Fukuyama

2024-06-05

Active, closed

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL

Janssen Research & Development, LLC

Phase 1

Chūōku, Kashiwa, Tokyo

2024-05-28

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Nagoya, Toyoake, Kashiwa, Matsuyam, Fukuoka, Kurume, Ōta, Sapporo

2024-05-24

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Chūōku, Fukuoka, Hirakata-shi, Kashiwa, Kōtoku, Matsuyama, Nakatogari, Okayama

2024-05-21

Active, closed

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

NCT06390995Ovarian Cancer, Solid Tumors

Takeda

Phase 1/2

Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Akashi, Shiwa-gun, Sendai

2024-05-20

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Nagoya, Kashiwa, Nankoku, Kitaadachi-gun, Chūō, Koto, Fukuoka, Osaka

2024-05-03

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo

2024-04-29

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu

2024-04-14

Recruiting

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942Advanced Solid Tumor

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1

308

Kashiwa, Kotoku

2024-04-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Nagoya, Kashiwa, Matsuyama, Ōsaka-sayama, Nagaizumi-cho, Chuo-ku, Koto-ku, Saitama

2024-04-10

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai

2024-04-03

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa

2024-03-12

Active, closed

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

490

Chūōku, Kashiwa, Kōtō City, Kyoto

2024-03-05

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Fukuoka, Kashiwa, Kōtoku, Nagoya, Ogaki-shi, Osaka, Sunto-gun, Tokyo

2024-03-04

Active, closed

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485Advanced Solid Tumor

DrugsValemetostat Tosylate·Dato-DXd·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1

210

Chūōku, Fukuoka, Kashiwa, Kōtoku, Nagoya, Osaka, Ōsaka-sayama, Shizuoka

2024-02-22

Active, closed

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

DrugsVepdegestrant·Atirmociclib

Pfizer

Phase 1/2

Kashiwa, Yokohama, Chuo-ku, Tokyo

2024-02-19

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

NCT06262919BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

DrugDabrafenib/trametinib

Novartis Pharmaceuticals

Observational

110

Nagakute, Nagoya, Toyohashi, Toyota, Daisen, Chiba, Funabashi, Kashiwa

2024-02-09

Active, closed

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

200

Tōon, Nishinomiya, Kashiwa, Osaka

2024-02-01

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugDocetaxel

Kyowa Kirin Co., Ltd.

Phase 1

101

Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata

2024-01-18

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553Advanced Solid Tumors That Are MTAP Deficient

DrugsAZD3470·Dato-DXd

AstraZeneca

Phase 1/2

334

Chūōku, Kashiwa

2024-01-18

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Toyoake, Kashiwa, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai

2023-12-31

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka

2023-12-29

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sendai, Bunkyo Ku, Yonago

2023-12-21

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157Neoplasms

DrugsMomelotinib·Ruxolitinib

Janssen Research & Development, LLC

Phase 1

300

Bunkyō City, Kashiwa

2023-12-20

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Toyoake, Hirosaki, Kashiwa, Matsuyama, Fukuoka, Kurume, Ōta, Himeji

2023-12-15

Active, closed

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

NCT06084884Hepatocellular Carcinoma

DrugAZD5851

AstraZeneca

Phase 1/2

Kashiwa, Osakasayama-shi

2023-12-14

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe

2023-12-14

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

Chūōku, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi

2023-12-13

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata

2023-12-06

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

Kashiwa, Nagoya, Yamagata

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Mitaka-shi, Nagoya, Osaka, Sendai

2023-12-04

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer

DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant

BeOne Medicines

Phase 1

433

Nagoya, Kashiwa, Suntogun

2023-12-01

Active, closed

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

NCT06057038Malignant Solid Tumor

DrugsGEN1042·Adrucil·Cisplatin·Carboplatin

Genmab

Phase 1

Kashiwa, Tokyo

2023-11-24

Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma

DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

914

Kashiwa

2023-11-20

Active, closed

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497Relapsed or Refractory T-cell Lymphomas

DrugGolcadomide

Bristol-Myers Squibb

Phase 1/2

Anjo-shi, Nagoya, Toyohashi, Kamogawa, Kashiwa, Narita, Iizuka, Kitakyushu-shi

2023-11-20

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Nagoya, Toyoake, Kashiwa, Matsuyama, Otashi, Takarazuka, Kanazawa, Yokohama

2023-11-12

Recruiting

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

NCT06248411Advanced or Metastatic Solid Tumors

Kyowa Kirin Co., Ltd.

Phase 1

189

Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai

2023-11-01

Active, closed

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

NCT06049212Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)

DrugsSacituzumab tirumotecan·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

Nagoya, Kashiwa, Matsuyama, Yokohama, Hirakata, Nagaizumi-cho,Sunto-gun, Chuo-ku

2023-10-26

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Nagakute, Abiko, Kashiwa, Sakura, Matsuyama, Kitakyushu, Kurume, Maebashi

2023-10-25

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Bunkyō City, Fukuoka, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Okayama

2023-10-24

Active, closed

A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06081829Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic

DrugIvosidenib

Servier

Phase 2

Kashiwa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo, Yokohama

2023-10-10

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsTRK-950·Ramucirumab·Paclitaxel

Toray Industries, Inc

Phase 2

146

Yokohama, Shinden, Nagaizumi-cho, Chūōku, Kashiwa, Kōtoku

2023-10-04

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor

Daiichi Sankyo

Phase 1/2

590

Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Osaka, Ōsaka-sayama, Sapporo

2023-08-18

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Chūōku, Kanazawa, Kashiwa, Kyoto, Osaka, Sendai, Ube, Wakayama

2023-08-16

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Nagoya, Kashiwa, Chuo-ku

2023-08-09

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

392

Chūōku, Kashiwa, Kōtoku

2023-07-11

Active, closed

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644Advanced Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

111

Kanazawa, Kashiwa, Matsuyama, Musashino-shi, Osakasayama-shi, Yokohama

2023-06-27

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

Kashiwa

2023-06-27

Active, closed

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

NCT06398743Colorectal Cancer

Exact Sciences Corporation

Observational

416

Kashiwa, Sapporo, Kita-gun

2023-06-20

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Hidaka-shi, Kashiwa, Kōtoku, Sunto-gun, Tokyo

2023-06-05

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Kurume, Akashi, Hirakata, Kashiwa, Nagoya, Ōsaka-sayama, Sapporo, Sendai

2023-06-01

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730Esophageal Squamous Cell Carcinoma

DrugsMK-4830·Steroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

230

Nagoya, Kashiwa, Kitaadachi-gun, Nagaizumi-cho,Sunto-gun, Chuo-ku

2023-05-16

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

NCT05629234Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

Kashiwa

2023-05-08

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Chūōku, Kashiwa, Yokohama

2023-04-24

Active, closed

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05704049Relapsed/Refractory Multiple Myeloma

DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab

Sanofi

Phase 2

118

Kashiwa, Okayama

2023-04-05

Recruiting

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

NCT06159478Low-grade Glioma, Pancreatic Cancer

DrugBinimetinib

National Cancer Center, Japan

Phase 2

Kashiwa, Sapporo, Kyoto, Sendai, Chuo-ku, Fukuoka

2023-03-29

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Nagoya, Chiba, Kashiwa, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yahaba

2023-03-15

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Nagoya, Chiba, Kashiwa, Sapporo, Yokohama, Suita, Ina-machi, Bunkyo-ku

2023-03-03

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Chūōku, Kashiwa, Sunto-gun

2023-01-16

Active, closed

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128Colitis Ulcerative

DrugDupilumab

Sanofi

Phase 2

Nagoya, Kashiwa, Kitakyushu, Sapporo, Kamakura, Shimizu, Bunkyo, Kyoto

2023-01-12

Active, closed

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013Crohn Disease, Colitis, Ulcerative

DrugDuvakitug

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

247

Kashiwa, Minato, Sakura, Shinjuku, Toyama

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Nagoya, Kashiwa, Kitakyushu-shi, Sapporo, Higashiibaraki, Kanazawa, Shiwa-gun Yahaba-cho, Kamakura

2023-01-10

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

Chūōku, Kashiwa, Kōtoku

2022-12-21

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Kashiwa, Nagareyama-shi, Maebashi, Nishinomiya, Ikoma, Saitama-shi, Shimotsuke, Bunkyo-ku

2022-12-16

Active, closed

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer

DrugPF-07799933

Pfizer

Phase 1

148

Kashiwa, Hirakata

2022-11-30

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

NCT05584670Solid Tumor

DrugsSAR445877·ADG126·Zirabev·Erbitux

Sanofi

Phase 1/2

542

Kashiwa

2022-11-29

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa

2022-11-28

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

284

Kashiwa

2022-11-04

Recruiting

Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel

NCT06043921Pancreatic Cancer

Invitae Corporation

Observational

150

Kashiwa

2022-11-01

Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms

DrugsPF-08046054·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

714

Kashiwa, Nagaizumi-cho

2022-10-25

Active, closed

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Kashiwa

2022-10-03

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Abiko, Chikushino-shi, Fukuoka, Fukuoka-ken, Hiroshima, Kagoshima, Kashihara, Kashiwa

2022-09-27

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Kashiwa, Kitakyushu-shi, Sapporo, Higashiibaraki, Shiwa-gun Yahaba-cho, Kamakura, Iruma, Koshigaya

2022-09-20

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi

2022-09-06

Active, closed

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

DrugJNJ-80948543

Janssen Research & Development, LLC

Phase 1

167

Kashiwa, Nagoya, Tokyo

2022-08-18

Active, closed

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

NCT05463952Breast Neoplasms

DrugVepdegestrant

Pfizer

Phase 1

Nagoya, Kashiwa, Chuo-ku

2022-08-16

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Kashiwa, Tokyo

2022-08-03

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa

2022-08-03

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto

2022-07-20

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Yokohama, Sendai, Niigata

2022-06-08

Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

DrugsASP2138·Ramucirumab·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 1

398

Nagoya, Kashiwa, Yokohama, Sakai, Suita, Chuo-ku, Koto-ku

2022-06-07

Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

NCT05101070Solid Tumors

DrugsAvastin·Keytruda·Bevacizumab·Pembrolizumab

Shionogi

Phase 1/2

282

Kashiwa, Suita, Chuo Ku

2022-05-30

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Chūōku, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun, Kōtoku

2022-05-16

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Nagoya, Kashiwa, Kisarazu, Sakura, Sapporo, Kobe, Kanazawa, Kita

2022-04-14

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab·Lenvatinib

AstraZeneca

Phase 3

760

Chūōku, Fukuoka, Hiroshima, Kashihara-shi, Kashiwa, Kumamoto, Mitaka-shi, Morioka

2022-03-28

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai

2022-03-24

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Toyoake, Kashiwa, Sakura, Tōon, Sapporo, Yokohama, Kashihara, Sakai

2022-03-15

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

Chūōku, Kashiwa, Kōtoku, Nagaizumi-chō, Osaka, Ōsaka-sayama, Yokohama

2022-03-09

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka

2022-02-21

Active, closed

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone

GlaxoSmithKline

Phase 3

Nagoya, Kamogawa, Kashiwa, Matsuyama, Fukushima, Maebashi, Shibukawa, Numakunai

2022-02-10

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Himeji-shi, Hiroshima, Kashiwa, Kurume-shi, Natori-shi, Niigata, Osaka, Sendai

2022-02-07

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

Kashiwa, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun Yahaba-cho

2022-02-03

Active, closed

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

NCT05034887Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugTrastuzumab deruxtecan

National Cancer Center Hospital East

Phase 2

Kashiwa

2022-01-31

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Nagoya, Kashiwa, Himeji, Yokohama, Niigata, Nakatogari, Koto, Yonago

2021-12-20

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Kashiwa, Yokohama, Nakatogari, Chuo-ku, Koto

2021-12-17

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

643

Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Shiwa-gun Yahaba-cho, Kawasaki

2021-12-13

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Bunkyō City, Hiroshima, Kashiwa, Nagoya, Osaka, Osaka Sayama Shi, Sendai, Shimotsuke

2021-12-10

Active, closed

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

NCT04745988Gastric Cancer

DrugsLevofolinate·Fluorouracil·Lenvatinib·Docetaxel

National Cancer Center Hospital East

Phase 2

Kashiwa

2021-11-11

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai

2021-10-28

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sakai, Sunto, Chuo-ku

2021-10-25

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Fukuoka, Gifu, Higashiibaraki-gun, Isehara, Kamakura-shi, Kashiwa, Koshigaya, Kumamoto

2021-10-14

Active, closed

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer

DrugSabestomig

AstraZeneca

Phase 1/2

136

Chūōku, Kashiwa

2021-09-28

Active, closed

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

NCT06540261Unresectable Colorectal Cancer

DrugsMagrolimab·Levofolinate·Fluorouracil·Cetuximab

Ono Pharmaceutical Co., Ltd.

Phase 1

Toyoake, Chiba, Kashiwa, Sapporo, Kobe, Kawasaki, Yokohama, Kurashiki

2021-09-23

Active, closed

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523Non-Small-Cell Lung Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

212

Kashiwa, Niigata, Sendai, Tokyo

2021-09-14

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Nagoya, Chiba, Kashiwa, Kotoku, Yokohama

2021-09-13

Active, closed

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811Non Small Cell Lung Cancer

DrugTaletrectinib

Nuvation Bio Inc.

Phase 2

217

Fukuoka, Kashiwa, Miyagi, Nagoya, Osaka, Shizuoka, Tokyo

2021-09-01

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Nagoya, Kashiwa, Sapporo, Kanazawa, Chuo-ku, Wakayama

2021-07-19

Active, closed

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634Prostatic Neoplasms

DrugPasritamig

Janssen Research & Development, LLC

Phase 1

216

Kashiwa, Yokohama

2021-07-13

Active, closed

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT04738942Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

Toyota, Hirosaki, Kashiwa, Sakura, Chikushino-shi, Sapporo, Nishinomiya, Kamakura

2021-06-04

Active, closed

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma

DrugValemetostat Tosylate

Daiichi Sankyo

Phase 2

155

Nagoya, Kashiwa, Sapporo, Chuo Ku, Fukuoka, Kagoshima, Kyoto, Nagasaki

2021-06-03

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 1/2

1,109

Kashiwa

2021-05-27

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

150

Bunkyō, Bunkyō City, Kashiwa, Kobe, Tokyo, Yokohama

2021-05-26

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Nagoya, Chūōku, Gifu, Kashiwa, Kobe, Kochi, Kōtoku, Matsuyama

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Fukuoka, Fukushima, Kanazawa, Kashiwa, Kobe, Maebashi, Nagoya, Sapporo

2021-05-19

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Nagoya, Hirosaki, Chiba, Kashiwa, Matsuyama, Fukuoka, Kure, Sapporo

2021-05-12

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

1,688

Toyoake, Kashiwa, Tōon, Sapporo, Yokohama, Kashihara, Sayama, Suita

2021-04-14

Active, closed

A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

NCT04721977Breast Cancer

DrugsTucatinib·Herceptin·Xeloda·Trastuzumab

Pfizer

Phase 2

Nagoya, Kashiwa, Matsuyama, Sapporo, Akashi, Nishinomiya, Tsukuba, Yokohama

2021-04-08

Recruiting

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

NCT04547166Metastatic Colorectal Cancer

DrugsHLX04·Serplulimab·Bevacizumab

Shanghai Henlius Biotech

Phase 2/3

568

Kashiwa

2021-03-10

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231Carcinoma, Renal Cell

DrugsBelzutifan·Cabozantinib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

747

Toyoake, Kashiwa, Sakura, Sapporo, Kobe, Yokohama, Kashihara, Sakai

2021-02-25

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Nagoya, Kashiwa, Osaka, Chuo Ku, Koto Ku

2021-02-24

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Kashiwa, Tokyo, Matsuyama, Sapporo, Akashi, Chiba, Ariake, Sendai

2021-02-02

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Fukuoka, Fukushima, Fukuyama, Hokkaido, Kashiwa, Kyoto, Matsuyama, Mie

2021-01-13

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi

2021-01-10

Active, closed

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

NCT04524000Advanced Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 2

Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita

2021-01-08

Active, closed

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

102

Chūōku, Kashiwa, Suita-shi

2020-12-30

Active, closed

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652Non-small Cell Lung Cancer

DrugsDato-DXd·Docetaxel

Daiichi Sankyo

Phase 3

605

Akashi, Chūōku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kōtoku

2020-12-21

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Chiba, Kashiwa, Sapporo, Kanazawa, Kawasaki, Yokohama, Nagoya, Osaka

2020-12-21

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata

2020-12-16

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku

2020-12-04

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kochi, Kurume-shi

2020-11-17

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole

Pfizer

Phase 2

320

Nagoya, Kashiwa, Yokohama, Chuo-ku

2020-11-16

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku

2020-10-19

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

Bunkyō City, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kishiwada, Kobe

2020-10-13

Active, closed

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

NCT04419532Solid Tumor, Advanced Cancer, Metastatic Solid Tumor

Daiichi Sankyo

Phase 1

Chūōku, Kashiwa, Kōtoku

2020-10-09

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Chiba, Chūōku, Fukuoka, Itabashi-ku, Kahoku-gun, Kashiwa, Kobe, Kōtoku

2020-10-08

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama

2020-10-02

Active, closed

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor

DrugsLY3410738·Durvalumab·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 1

200

Kashiwa, Yokohama, Suita-shi, Nakatogari, Chuo-ku

2020-10-01

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

Bunkyō City, Chūōku, Fukuoka, Himeji, Hirakata, Kanazawa, Kashiwa, Kurume

2020-09-30

Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)

DrugsAtirmociclib·Midazolam

Pfizer

Phase 1/2

430

Kashiwa

2020-09-23

Active, closed

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine

ADC Therapeutics S.A.

Phase 3

440

Nagoya, Toyohashi, Kashiwa, Matsuyama, Ōta, Sapporo, Kobe, Yokohama

2020-09-16

Recruiting

ONO-4538 Phase II Rollover Study (ONO-4538-98)

NCT04566380Pan-tumor

DrugsBinimetinib·Teysuno·Temozolomide·Ipilimumab

Ono Pharmaceutical Co., Ltd.

Phase 2

Chiba, Kashiwa, Matsuyama, Fukuoka, Kurume, Hiroshima, Sapporo, Akashi

2020-09-10

Active, closed

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

477

Chūōku, Kashiwa, Suita-shi

2020-08-18

Active, closed

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847Myelodysplastic Syndrome, Acute Myeloid Leukemia

DrugsVenclexta·Azacitidine·Venetoclax

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

170

Kashiwa, Bunkyo-ku, Yamagata

2020-08-07

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Hirosaki, Kashiwa, Kitakyusyu-shi, Chikushino-shi, Fukuoka, Kiryū, Chuo-ku, Sapporo-shi, Sapporo

2020-06-22

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Chūōku, Kashiwa

2020-06-03

Recruiting

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

NCT06636435Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer

Chiome Bioscience Inc.

Phase 1

Kashiwa, Yokohama, Niigata, Chūō

2020-06-01

Active, closed

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117Locally Advanced or Metastatic Malignant Solid Tumors

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Astellas Pharma Global Development, Inc.

Phase 2

329

Nagoya, Kashiwa, Ōsaka-sayama, Kitaadachi-Gun, Nakatogari, Chūō, Koto, Okayama

2020-03-10

Active, closed

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750Carcinoma, Renal Cell

DrugsBelzutifan·Everolimus

Merck Sharp & Dohme LLC

Phase 3

755

Toyoake, Kashiwa, Tōon, Sapporo, Yokohama, Kashihara, Sayama, Suita

2020-02-27

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944Non-Small Cell Lung Cancer

DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

261

Kashiwa, Sapporo, Kanazawa, Yokohama, Osaka Sayama-shi, Nakatogari, Chuo-ku, Koto

2020-02-17

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

Nagoya, Kashiwa, Sapporo, Kobe, Yokohama, Suita, Koto, Fukuoka

2020-02-11

Active, closed

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

NCT03975647HER2-positive Breast Cancer

DrugsTucatinib·Trastuzumab emtansine

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

466

Nagoya, Kashiwa, Hiroshima, Matsuyama, Fukuoka, Sapporo, Nishinomiya, Tsukuba

2019-10-02

Recruiting

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

NCT04288999Rectal Cancer Recurrent

National Cancer Center Hospital East

Phase 3

110

Chiba, Gifu, Hidaka, Hirakata, Hiroshima, Izumo, Kanazawa, Kashiwa

2019-10-01

Active, closed

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

NCT04078295Solid Neoplasms

DrugsE7389-LF·Nivolumab

Eisai Co., Ltd.

Phase 1/2

125

Nagoya, Kashiwa, Matsuya, Kurume, Akashi, Yokohama, Sendai, Chuo Ku

2019-09-05

Active, closed

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

701

Chūōku, Hirakata, Kashiwa, Kobe, Nagoya, Okayama, Shizuoka

2019-09-04

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Kashiwa, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Sendai, Tomitake, Kashihara

2019-07-24

Active, closed

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel

Eisai Inc.

Phase 1/2

301

Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Akashi, Kawasaki, Kamigyō-ku

2019-07-11

Active, closed

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Non-Small Cell Lung Cancer

DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib

AstraZeneca

Phase 3

587

Bunkyō City, Fukuoka, Hidaka-shi, Himeji-shi, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku

2019-07-02

Active, closed

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

NCT05696548Anaplastic Thyroid Cancer

DrugsLenvatinib·Nivolumab

National Cancer Center Hospital East

Phase 2

Nagoya, Kashiwa, Hokkaido, Akashi, Kobe, Yokohama, Sendai, Osaka

2019-07-02

Active, closed

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT03875235Biliary Tract Neoplasms

DrugDurvalumab

AstraZeneca

Phase 3

810

Chūōku, Kashiwa, Kitaadachi-gun, Mitaka-shi, Osaka, Suita-shi, Wakayama, Yokohama

2019-04-16

Active, closed

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine

Astellas Pharma Global Development, Inc.

Phase 2

393

Nagoya, Kashiwa, Sapporo, Yokohama, Kashihara, Bunkyo-ku, Chuo-ku, Koto-ku

2019-03-15

Active, closed

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

NCT03833700Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors

DrugE7386

Eisai Co., Ltd.

Phase 1

Nagoya, Kashiwa, Sapporo, Sendai, Nagaizumi-cho, Chuo Ku, Fukuoka, Osaka

2019-03-05

Active, closed

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

NCT03807778Non-Small Cell Lung Cancer

DrugMobocertinib

Takeda

Phase 1

Nagoya, Toyoake, Kashiwa, Kurume, Sapporo, Akashi, Kanazawa, Yokohama

2019-02-04

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

Nagoya, Kashiwa, Sapporo, Nishinomiya, Sagamihara, Kumamoto, Hidaka, Kitaadachi-gun

2018-12-27

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Nagoya, Kashiwa, Akashi, Kita-gun, Minato, Chiba, Fukuoka, Hiroshima

2018-12-17

Active, closed

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

NCT03742895Advanced Solid Neoplasms

DrugOlaparib

Merck Sharp & Dohme LLC

Phase 2

329

Nagoya, Kashiwa, Kyoto, Suita, Tokyo

2018-12-12

Active, closed

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

507

Fukuoka, Akashi, Kawasaki, Yokohama, Suita, Utsunomiya, Chiba, Kashiwa

2018-11-28

Active, closed

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

DrugsPonatinib·Imatinib·Cytarabine·Vincristine

Takeda

Phase 3

245

Chiba, Kashiwa, Fukushima, Sapporo, Isehara, Okayama

2018-10-04

Active, closed

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297Small Cell Lung Cancer

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

730

Bunkyō City, Chūōku, Fukuoka, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi, Nagoya

2018-09-27

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Akashi, Himeji

2018-08-21

Active, closed

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

NCT03521154Non Small Cell Lung Cancer (Stage III)

DrugOsimertinib

AstraZeneca

Phase 3

216

Hiroshima, Kanazawa, Kashiwa, Nagoya, Niigata, Osaka, Sakaishi, Sapporo

2018-07-19

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Nagoya, Kashiwa, Matsuyama, Sapporo, Kobe, Suita, Hidaka, Kitaadachi-gun

2018-06-21

Active, closed

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed

DrugsRucaparib·Opdivo·Nivolumab

pharmaand GmbH

Phase 3

1,097

Tsukuba, Kashiwa, Kurume, Yokohama, Maebashi, Ota-shi, Naka, Akashi

2018-05-14

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643Non-small Cell Lung Cancer

DrugsPemetrexed·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

797

Nagoya, Kashiwa, Kitakyushu, Akashi, Kawasaki, Yokohama, Yufu, Fukushima

2018-04-24

Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)

DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide

Pfizer

Phase 1

453

Kashiwa

2018-04-17

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

629

Chiba, Hirosaki, Kashiwa, Kita Gun, Kobe, Koshigaya, Matsuyama, Miyazaki

2018-03-23

Active, closed

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer

DrugDato-DXd

Daiichi Sankyo Co., Ltd.

Phase 1

890

Nagoya, Koto-Ku, Shinagawa-Ku, Chūōku, Kashiwa

2018-01-31

Recruiting

Dabrafenib and/or Trametinib Rollover Study

NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Phase 4

100

Kashiwa, Chuo Ku

2018-01-26

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Nagoya, Hirosaki, Kashiwa, Matsuyama, Kure, Sapporo, Kanazawa, Yokohama

2017-12-18

Active, closed

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

NCT03252808Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV

DrugsTS-1·Abraxane·Nab-paclitaxel·Gemcitabine

Takara Bio Inc.

Phase 1

Nagoya, Chiba, Kashiwa, Yokohama, Osaka, Chūōku, Koto-Ku

2017-09-25

Active, closed

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

NCT03207672Solid Tumor

DrugE7389-LF

Eisai Co., Ltd.

Phase 1

140

Kashiwa, Sapporo, Nishinomiya, Yokohama, Hidaka, Bunkyo-ku, Chuo-ku, Koto-ku

2017-08-18

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Ōta, Hiroshima, Sapporo

2017-07-12

Active, closed

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616Non Small Cell Lung Cancer NSCLC

DrugsTremelimumab·Abraxane·Durvalumab·Pemetrexed

AstraZeneca

Phase 3

1,186

Bunkyō City, Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku

2017-06-01

Active, closed

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor

DrugSelpercatinib

Eli Lilly and Company

Phase 1/2

857

Nagoya, Kashiwa, Sapporo, Akashi, Kanazawa, Osaka Sayama-shi, Nagaizumi-cho,Sunto-gun, Chuo-ku

2017-05-02

Active, closed

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

NCT03155061Advanced or Metastatic Solid Tumors

DrugsONO-4578·Nivolumab

Ono Pharmaceutical Co., Ltd.

Phase 1

183

Nagoya, Toyoake, Kashiwa, Matsuyama, Fukuoka, Ōta, Sapporo, Yahaba-cho

2017-04-19

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

Chūōku, Fukuoka, Fukushima, Himeji-shi, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi

2017-03-27

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors

DrugRepotrectinib

Turning Point Therapeutics, Inc.

Phase 1/2

500

Tōon, Sapporo, Yokohama, Osaka, Chuo-ku, Yonago, Kashiwa, Nagoya

2017-03-07

Active, closed

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

NCT02716116Carcinoma, Non-Small-Cell Lung

DrugMobocertinib

Takeda

Phase 1/2

334

Kashiwa, Kurume-shi, Sendai, Ōsaka-sayama

2016-06-16

Active, closed

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Non-Small-Cell Lung Cancer

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

751

Chūōku, Hyōgo, Kashiwa, Kurume, Nagoya, Niigata, Osaka, Tokyo

2016-05-24

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Bunkyō City, Fukuoka, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kitakyushu-shi, Kobe

2015-10-21

Active, closed

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

NCT02519348Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab·Bevacizumab

MedImmune LLC

Phase 2

433

Chūōku, Kashiwa, Osakasayama-shi

2015-10-19

Active, closed

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448Metastatic Non-Small Cell Lung Cancer

DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib

Eli Lilly and Company

Phase 3

545

Nagoya, Kashiwa, Tōon, Kurume, Asahikawa, Akashi, Amagashiki, Himeji

2015-05-06

Active, closed

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736Prostatic Neoplasms

DrugsZytiga·Apalutamide·Abiraterone acetate·Prednisone

Aragon Pharmaceuticals, Inc.

Phase 3

982

Fukuoka, Kanazawa, Kashiwa, Kita-Gun, Kumamoto, Kurume, Matsuyama, Miyazaki

2014-11-26

Active, closed

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466Advanced Non Small Cell Lung Cancer

DrugsSavolitinib·Selumetinib·Osimertinib·Durvalumab

AstraZeneca

Phase 1

344

Chūōku, Habikino-shi, Hirakata-shi, Kashiwa, Nagoya

2014-08-05

Active, closed

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703Breast Neoplasms

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

669

Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Sapporo, Nishinomiya, Kawasaki

2014-07-22

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa

2014-04-22

Active, closed

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204Prostatic Neoplasms

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,207

Akita, Fukuoka, Gifu, Hakodate, Hiroshima, Hokkaido, Kanazawa, Kashiwa

2013-10-14

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kashiwa

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 316 of those studies with a site in Kashiwa.

How many clinical trials are recruiting in Kashiwa?

157 of the 316 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 157 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kashiwa), 316 studies
Phase	Studies	Recruiting	Share
Phase 3	143	56	45.3%
Phase 1/2	57	40	18%
Phase 1	53	26	16.8%
Phase 2	48	24	15.2%
Phase 2/3	8	7	2.5%
Observational	5	2	1.6%
Not applicable	1	1	0.3%
Phase 4	1	1	0.3%

Most active sponsors

Lead sponsors with the most studies (Kashiwa)
Lead sponsor	Studies	Recruiting
AstraZeneca	72	33
Merck Sharp & Dohme LLC	40	20
Pfizer	20	10
Daiichi Sankyo	19	9
Eli Lilly and Company	18	7
Janssen Research & Development, LLC	17	8
Bristol-Myers Squibb	13	9
Novartis Pharmaceuticals	10	5
Astellas Pharma Global Development, Inc.	8	4
Ono Pharmaceutical Co., Ltd.	7	4

→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.